Canaccord Cuts Hims & Hers Price Target After Novo Nordisk Sues Over Compounded Semaglutide
Canaccord Genuity trimmed its price target on Hims & Hers to $30 from $68 while retaining a Buy rating after Novo Nordisk sued the telehealth firm over alleged patent infringement related to mass-marketed, unapproved semaglutide products. The move follows Hims’ brief announcement — and reversal — about offering a compounded oral semaglutide pill, a…